The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 344:1007-1009 March 29, 2001 Number 13
NextNext

Varicella Vaccine — The First Six Years

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Vazquez, M.
-PubMed Citation
The live attenuated varicella vaccine is the only vaccine licensed for the prevention of a disease caused by a human herpesvirus. The origin of the vaccine can be traced back to 1952, when Weller and Stoddard recovered varicella–zoster virus by cell culture and reported the first successful propagation of a herpesvirus in vitro.1 In 1974, Takahashi and colleagues attenuated the wild-type Oka strain by serial passage in guinea-pig and human cells, while preserving its immunogenicity after subcutaneous inoculation.2 Clinical trials of varicella vaccine were initiated in the United States in 1980, leading to approval by the Food and Drug Administration . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.